A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).
Tom Samuel Waddell(Royal Marsden NHS Foundation Trust), David Cunningham(Royal Marsden NHS Foundation Trust), Jonathan Wadsley(Weston Park Cancer Centre), Justin S. Waters(Maidstone Hospital), Ian Chau(Universitat Autònoma de Barcelona), Gary Middleton(University of Birmingham), Timothy Iveson(University Hospital Southampton NHS Foundation Trust), Tom Crosby(Southampton General Hospital), Alicia Okines(Royal Marsden NHS Foundation Trust), Wasat Mansoor(The Christie NHS Foundation Trust), Claire Saffery(Royal Marsden NHS Foundation Trust), Yolanda Barbáchano(Royal Marsden NHS Foundation Trust), David González de Castro(Complejo Hospitalario de Salamanca), David Ferry(Eli Lilly (United States)), David B. Smith(Wirral University Teaching Hospital NHS Foundation Trust), Sarah Slater(Barts Health NHS Trust), Fareeda Y. Coxon(Newcastle upon Tyne Hospitals NHS Foundation Trust), Andrew Wotherspoon(Université Libre de Bruxelles), Stephen Falk(At Bristol)
Cited by 49
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k